Research Topics
Genomes and Genes | Robert PirkerSummaryAffiliation: Medical University of Vienna Country: Austria Publications
| Collaborators
|
Detail Information
Publications
Two- versus three-drug combinations in the chemotherapy of advanced non-small-cell lung cancerRobert Pirker
Department of Internal Medicine I, University of Vienna Medical School, , 1090 Vienna, Austria
Lung Cancer 38:S53-5. 2002..Thus three-drug combinations have not convincingly been demonstrated to be superior to two-drug combinations and should not be considered as standard protocols in advanced NSCLC...- Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancerR Pirker
Division of Oncology, Department of Internal Medicine I, Medical University Vienna, Wahringer Gurtel 18 20, A 1090, Vienna, Austria
Lung 184:279-85. 2006..Four patients (15%) had febrile neutropenia. Full-dose, on-schedule dose-dense ACE chemotherapy is feasible with once-per-cycle pegfilgrastim support in extensive SCLC... - Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic ProgramMartin Filipits
Department of Medicine I, Medical University of Vienna, Vienna, Austria
Clin Cancer Res 13:3892-8. 2007..The purpose of our study was to determine whether multidrug resistance proteins (MRP) are of prognostic and/or predictive value in patients who were enrolled into the International Adjuvant Lung Cancer Trial (IALT)... 
EGFR-directed monoclonal antibodies in non-small cell lung cancerRobert Pirker
Department of Medicine I, Medical University of Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
Target Oncol 8:47-53. 2013..Cetuximab is also studied in combination with chemoradiotherapy in patients with locally advanced NSCLC...
Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agentRobert Pirker
Medical University Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
Support Care Cancer 21:987-92. 2013..The aim of this study was to examine the rate and timing of hemoglobin decline from <10 g/dL to <9 g/dL in cancer patients receiving chemotherapy...- Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX studyR Pirker
Department of Medicine I, Medical University Vienna, Vienna, Austria
Lung Cancer 77:376-82. 2012..The FLEX study is registered with ClinicalTrials.gov, number NCT00148798... - EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX studyRobert Pirker
Department of Medicine I, Medical University Vienna, Vienna, Austria
Lancet Oncol 13:33-42. 2012..To define patients benefiting most from cetuximab, we studied the association of tumour EGFR expression level with clinical outcome in FLEX study patients... - Targeted therapies in lung cancerRobert Pirker
Department of Medicine I, Medical University of Vienna, Vienna, Austria
Curr Pharm Des 15:188-206. 2009..In small cell lung cancer (SCLC), targeted therapies have also been studied but no clinical benefit could be demonstrated for these agents... - Darbepoetin alfa for the treatment of cancer-related anemia: an updateRobert Pirker
Medical University Vienna, Department of Internal Medicine I, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
Expert Rev Anticancer Ther 4:735-44. 2004..This review provides an overview of clinical trial results, particularly those exploring flexible, extended dosing schedules... - Therapy of advanced non-small-cell lung cancer (take home message)Robert Pirker
Department of Internal Medicine I, Medical University Vienna, Wahringer Gurtel 18, A 1090 Vienna, Austria
Lung Cancer 45:S259-62. 2004..This goal is usually achieved by one or more of the following treatment modalities: chemotherapy, radiotherapy, special palliative interventions and general supportive care measures... - Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposideRobert Pirker
Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
J Clin Oncol 26:2342-9. 2008.... - Once-weekly epoetin beta (30,000 IU) in anemic patients with lung cancer receiving chemotherapyRobert Pirker
Department of Internal Medicine I, Medical University Vienna, Wahringer Gurtel 18, A 1090 Vienna, Austria
Lung Cancer 55:89-94. 2007..Epoetin beta was well tolerated. This early intervention strategy with epoetin beta 30,000 IU once weekly is an effective and well-tolerated therapy for anemia in patients with lung cancer... - Safety considerations for erythropoietin treatment in patients with cancerRobert Pirker
Lung Cancer, Medical University of Vienna, Department of Internal Medicine I, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
Expert Opin Drug Saf 6:63-9. 2007..However, the association between erythropoietic proteins and outcome of anticancer therapy, including survival, requires further study... - Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancerRobert Pirker
Department of Internal Medicine I, Medical University of Vienna, Austria
Clin Lung Cancer 9:S109-15. 2008..Two phase III trials with chemotherapy with or without cetuximab have been performed in patients with advanced NSCLC. Other EGFR-directed MoAbs and TKIs are in earlier stages of clinical development... - Monoclonal antibodies against EGFR in non-small cell lung cancerRobert Pirker
Department of Medicine I, Medical University of Vienna, Austria
Crit Rev Oncol Hematol 80:1-9. 2011..Matuzumab and panitumumab have also been evaluated in phase II trials. Necitumumab is currently evaluated in combination with chemotherapy in two randomized phase III trials... - Chemotherapy of advanced non-small cell lung cancerRobert Pirker
Department of Medicine I, Medical University of Vienna, Vienna, Austria
Front Radiat Ther Oncol 42:157-63. 2010..Finally, the efficacy of new anticancer treatments should be assessed by several clinical endpoints with overall survival remaining the most important endpoint in patients with advanced NSCLC... - Therapy of small cell lung cancer with emphasis on oral topotecanRobert Pirker
Department of Medicine I, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
Lung Cancer 70:7-13. 2010..Thus topotecan is considered as the standard second-line chemotherapy in patients with small cell lung cancer... - Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshopRobert Pirker
Medical University of Vienna, Vienna, Austria
J Thorac Oncol 5:1706-13. 2010..Because EGFR mutation testing is not yet well established across Europe, biomarker-directed therapy only slowly emerges for the subset of NSCLC patients most likely to benefit: those with EGFR mutations... - Erythropoiesis-stimulating agents in patients with cancer: update on safety issuesRobert Pirker
Medical University of Vienna, Department of Medicine I, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
Expert Opin Drug Saf 8:515-22. 2009..Hypertension and thromboembolic events are the main side effects. The association between erythropoietic proteins and clinical outcome including survival warrants further studies... - Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study GroupMartin Filipits
Department of Internal Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
J Clin Oncol 23:1161-8. 2005..Therefore, we determined the impact of MRP1 expression on the clinical outcome of adjuvant therapy in patients with early-stage breast cancer... - Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialRobert Pirker
Medical University of Vienna, Vienna, Austria
Lancet 373:1525-31. 2009..We therefore compared chemotherapy plus cetuximab with chemotherapy alone in patients with advanced EGFR-positive non-small-cell lung cancer... - Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapyMargaretha Rudas
Department of Pathology, University of Vienna, Vienna, Austria
Breast Cancer Res Treat 81:149-57. 2003..Response to chemotherapy is not associated with pre- or postchemotherapy expression levels of these drug resistance proteins but time to progression may be influenced by prechemotherapy MRP1 expression... - Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancerGudrun Pohl
Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
Lung Cancer 54:63-7. 2006..05). In conclusion, the TIP regimen shows activity and good tolerance as induction chemotherapy in patients with locally advanced NSCLC... - High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelinGudrun Pohl
Department of Medicine I, Clinical Division of Oncology, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
J Clin Oncol 21:3594-600. 2003.... - Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic ProgramMartin Filipits
Department of Medicine I, Medical University of Vienna, Vienna, Austria
J Clin Oncol 25:2735-40. 2007..The purpose of our study was to determine whether cell cycle regulators are of prognostic and/or predictive value in patients who were enrolled onto the IALT... - Anemia in lung cancer: clinical impact and managementRobert Pirker
Department of Internal Medicine I, University of Vienna, Austria
Clin Lung Cancer 5:90-7. 2003..Oncologists must be aware of the clinical relevance of anemia and offer adequate treatment options to their patients... - Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapyGudrun Pohl
Department of Internal Medicine 1, Division of Oncology, University Hospital, Vienna, Austria
Breast Cancer Res Treat 78:97-103. 2003.... - EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastasesKatharina Schmid
Clinical Institute of Pathology and Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18 20, Vienna A 1090, Austria
Clin Cancer Res 15:4554-60. 2009..The present study compared the mutational status of EGFR, KRAS, and BRAF in primary tumors with the one in corresponding lymph node metastases... - Darbepoetin alfa: potential role in managing anemia in cancer patientsRobert Pirker
Department of Internal Medicine I, University of Vienna, Austria
Expert Rev Anticancer Ther 2:377-84. 2002..Thus, darbepoetin alfa has the potential to improve supportive care and thereby, cancer patients' quality of life, and might also impact on treatment outcome... - Predictive markers in the adjuvant therapy of non-small cell lung cancerMartin Filipits
Department of Medicine I, Medical University of Vienna, Vienna, Austria
Lung Cancer 74:355-63. 2011..After standardization of these tests and further validation studies, biomarkers might allow individualizing adjuvant treatment in patients with completely resected NSCLC in the future... - Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancerGerwin Heller
Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
Breast Cancer Res Treat 103:283-91. 2007..011, P = 0.02). Our findings suggest that TSLC1 and DAL-1 are involved in the pathogenesis of breast cancer and are frequently inactivated by methylation... - Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinomaBeata Herberger
Department of Medicine I, Medical University of Vienna, Vienna, Austria
Clin Cancer Res 13:4795-9. 2007..The purpose of our study was to determine the prognostic value of activated mTOR (p-mTOR) in patients with biliary tract adenocarcinoma (BTA), in order to strengthen the rationale for targeted therapy of BTA using mTOR inhibitors... - Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomasM Filipits
Division of Oncology, Department of Internal Medicine I, University of Vienna, Austria
Clin Cancer Res 6:3417-23. 2000..Thus, the reversal of LRP-mediated drug resistance may improve clinical outcome in diffuse large B-cell lymphoma in the future... - Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphomaMartin Filipits
Department of Internal Medicine I, Division of Oncology, University of Vienna, A 1090 Vienna, Austria
Clin Cancer Res 8:729-33. 2002..In conclusion, high cyclin D3 expression is an independent predictive and prognostic factor associated with poor clinical outcome in patients with diffuse large B-cell lymphoma... - New drugs in the palliative chemotherapy of advanced non-small-cell lung cancerR Malayeri
Division of Oncology, Department of Internal Medicine I, University of Vienna Medical School, Austria
Onkologie 24:416-21. 2001..Second-line chemotherapy prolongs survival in selected patients and should be particularly offered to patients with good performance status... - High D-dimer levels are associated with poor prognosis in cancer patientsCihan Ay
Clinical Division of Hematology and Hemostaseology Department of Medicine I, Vienna, Austria
Haematologica 97:1158-64. 2012..Increased levels of D-dimer, which is a degradation product of cross-linked fibrin, indicate a global activation of hemostasis and fibrinolysis... - Adjuvant and induction chemotherapy in non-small cell lung cancerR Pirker
Department of Internal Medicine I, University of Vienna, Austria
Ann Oncol 10:71-6. 1999..Thus adjuvant chemotherapy with both improved chemotherapy protocols and improved anti-emetics is currently re-evaluated in several randomised trials on large patient populations... - [Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms]Wolfgang Hilbe
, , Schwerpunkt Onkologie, Innsbruck, Austria
Wien Klin Wochenschr 119:259-66. 2007 - Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancerJohan Vansteenkiste
Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
Invest New Drugs 23:263-9. 2005..The present study did not show any advantage, in response rate or secondary endpoints, with aprinocarsen; however, the toxicity was not unduly increased, and aprinocarsen regimen was safely administered... - Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancerPieter E Postmus
Department of Pulmonary Diseases, Vrije Universiteit Medical Cetner, Amsterdam, Netherlands
Lung Cancer 42:S3-6. 2003 - Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapyJohan Vansteenkiste
Respiratory Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
J Natl Cancer Inst 94:1211-20. 2002..This phase III study compared the safety and efficacy of darbepoetin alfa with placebo in patients with lung cancer receiving chemotherapy... - Erythropoietin in cancer: an updateJozsef Tovari
Department of Tumor Biology, National Koranyi Institute of Pulmonology, Piheno u 1, Budapest, H 1529, Hungary
Curr Mol Med 8:481-91. 2008..The current paper provides an update on the biology of EPO, and discusses its utility in the treatment of cancer patients... - Highly refractory acute myeloid leukemiaWolfgang Füreder
Division of Hematology and Hemostaseology, The University of Vienna, Austria
Wien Klin Wochenschr 116:561-4. 2004..Overall, patients with highly refractory AML are characterized by a high incidence of complex cytogenetic aberrations and marked expression of drug transporters... - DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapyKen A Olaussen
Laboratory of Radiobiology and Oncology, , Fontenay aux Roses, University of Paris 11, Paris, France
N Engl J Med 355:983-91. 2006..49 to 0.90; P=0.009). CONCLUSIONS: Patients with completely resected non-small-cell lung cancer and ERCC1-negative tumors appear to benefit from adjuvant cisplatin-based chemotherapy, whereas patients with ERCC1-positive tumors do not...